Table 2

Characteristics of 383 patients with SARS-CoV-2/COVID-19 by status of progression to severe COVID-19

CharacteristicsNonsevere (n = 292, 76.2%)Severe (n = 91, 23.8%)P value
Age, years, median (IQR)44.5 (34–57)61 (52–65)<0.001
Male, n (%)125 (42.8)58 (63.7)<0.001
Epidemiological information, n (%)
 From Hubei160 (54.79)55 (60.44)0.04
 Not been to Hubei, but infected by individuals from Hubei112 (38.36)24 (26.37)
 Without any clear contact history20 (6.85)12 (13.19)
Personal disease history, n (%)
 Diabetes
  No282 (96.58)79 (86.81)0.001
  Yes10 (3.42)12 (13.19)
 Hypertension
  No255 (87.33)70 (76.92)0.02
  Yes37 (12.67)21 (23.08)
 Cardiovascular diseases
  No274 (93.84)74 (81.32)0.001
  Yes18 (6.16)17 (18.68)
 Liver disease
  No277 (94.86)86 (94.51)0.54
  Yes15 (5.14)5 (5.49)
 Cancer
  No291 (99.66)87 (95.6)0.01
  Yes1 (0.34)4 (4.4)
 COPD
  No273 (93.49)78 (85.71)0.03
  Yes19 (6.51)13 (14.29)
Initial symptoms, n (%)
 Fever
  No104 (35.62)12 (13.19)<0.001
  Yes188 (64.38)79 (86.81)
 Cough
  No187 (64.04)47 (51.65)0.03
  Yes105 (35.96)44 (48.35)
 Fatigue
  No279 (95.55)88 (96.7)0.77
  Yes13 (4.45)3 (3.3)
 Headache
  No284 (97.26)91 (100)0.21
  Yes8 (2.74)0 (0)
 Diarrhea
  No285 (97.6)87 (95.6)0.30
  Yes7 (2.4)4 (4.4)
 Sore throat
  No288 (98.63)91 (100)0.58
  Yes4 (1.37)0 (0)
 Nasal congestion
  No289 (98.97)90 (98.9)1.00
  Yes3 (1.03)1 (1.1)
Disease progression, days,  median (IQR)
 From onset to hospitalization3 (1–6)4 (2–7)0.01
 From onset to discharge22 (16–30)33.5 (24–41)<0.001
Death, n (%)
 No292 (100)88 (96.7)0.01
 Yes0 (0)3 (3.3)